SAN DIEGO, June 02, 2025 -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the...
Jeff Collins will participate on a panel titled "Funding Innovation, Cross-Border Investments and M&A Trends" at the US India BioPharma & Healthcare Summit in Cambridge, MA
News | 05. 14. 2009
